PMID- 34201809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210726
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 11
IP  - 7
DP  - 2021 Jun 23
TI  - Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in 
      Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian 
      A/B Testing Approach.
LID - 10.3390/diagnostics11071144 [doi]
LID - 1144
AB  - The aim of this study was to evaluate the probability of pathologic complete 
      regression (pCR) by the BRCA1 gene mutation status in patients with 
      triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. The 
      study involved 143 women (mean age 55.4 +/- 13.1 years) with TNBC. The BRCA1 
      mutation was observed in 17% of the subjects. The most commonly used (85.3%) 
      chemotherapy regimen was four cycles of adriamycine and cyclophosphamide followed 
      by 12 cycles of paclitaxel (4AC + 12T). The differences between 
      clinico-pathological factors by BRCA1 status were estimated. Odds ratios and 95% 
      confidence intervals for pCR vs. non-pCR were calculated using logistic 
      regression. The probability distribution of pCR based on BRCA1 status was 
      estimated using beta distributions. The presence of T3-T4 tumours, cancer in 
      stages II and III, lymphovascular invasion, and the use of chemotherapy schedules 
      other than 4AC + 12T significantly decreased the odds of pCR. It was established 
      that there was a 20% chance that pCR in patients with the BRCA1 mutation was 50% 
      or more times as frequent than in patients without the mutation. Thus, the BRCA1 
      mutation can be a predictive factor for pCR in patients with TNBC.
FAU - Kedzierawski, Piotr
AU  - Kedzierawski P
AUID- ORCID: 0000-0002-1835-8794
AD  - Department of Oncology, Institute of Health Sciences, Collegium Medicum, Jan 
      Kochanowski University, 25-713 Kielce, Poland.
AD  - Radiotherapy Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.
FAU - Macek, Pawel
AU  - Macek P
AUID- ORCID: 0000-0001-9755-7507
AD  - Department of Oncology, Institute of Health Sciences, Collegium Medicum, Jan 
      Kochanowski University, 25-713 Kielce, Poland.
AD  - Department of Epidemiology and Cancer Control, Holycross Cancer Centre, 25-734 
      Kielce, Poland.
FAU - Ciepiela, Izabela
AU  - Ciepiela I
AD  - Radiotherapy Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.
FAU - Kowalik, Artur
AU  - Kowalik A
AUID- ORCID: 0000-0002-3718-999X
AD  - Division of Medical Biology, Institute of Biology, Jan Kochanowski University, 
      25-406 Kielce, Poland.
AD  - Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, 
      Poland.
FAU - Gozdz, Stanislaw
AU  - Gozdz S
AD  - Department of Oncology, Institute of Health Sciences, Collegium Medicum, Jan 
      Kochanowski University, 25-713 Kielce, Poland.
AD  - Clinical Oncology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.
LA  - eng
PT  - Journal Article
DEP - 20210623
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC8306462
OTO - NOTNLM
OT  - BRCA1
OT  - Bayesian statistics
OT  - breast cancer
OT  - pathologic complete regression
OT  - triple-negative breast cancer
COIS- The authors report no conflicts of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/23
CRDT- 2021/07/02 01:12
PHST- 2021/04/20 00:00 [received]
PHST- 2021/06/18 00:00 [revised]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/07/02 01:12 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/23 00:00 [pmc-release]
AID - diagnostics11071144 [pii]
AID - diagnostics-11-01144 [pii]
AID - 10.3390/diagnostics11071144 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2021 Jun 23;11(7):1144. doi: 10.3390/diagnostics11071144.